Forteris Wealth Management Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 6,150 shares of the biopharmaceutical company’s stock, valued at approximately $755,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Invesco Ltd. lifted its stake in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. Legal & General Group Plc lifted its stake in Gilead Sciences by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after buying an additional 414,454 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Gilead Sciences by 5.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after buying an additional 400,002 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Insider Transactions at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer directly owned 176,191 shares in the company, valued at $24,835,883.36. This represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 299,280 shares of company stock worth $42,920,450 in the last ninety days. Insiders own 0.30% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Report on GILD
Gilead Sciences Trading Down 0.9%
GILD stock opened at $138.55 on Friday. The company has a market cap of $171.97 billion, a price-to-earnings ratio of 20.47, a PEG ratio of 1.86 and a beta of 0.39. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The business has a fifty day simple moving average of $144.65 and a 200-day simple moving average of $131.10. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 48.45%.
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Wells Fargo reiterated a buy rating on Gilead, supporting investor confidence in the company’s longer-term fundamentals. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
- Positive Sentiment: The U.S. Department of State expanded a partnership with Gilead and The Global Fund to provide 1 million doses of lenacapavir, boosting addressable market and public-health visibility for Gilead’s HIV prevention franchise. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
- Positive Sentiment: Citigroup coverage remains constructive, with at least one analyst publicly saying GILD’s stock is expected to rise — a counterbalance to short‑term caution. Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Citigroup Analyst Says
- Neutral Sentiment: Two insiders (including the CFO) sold small percentages of their positions via pre‑arranged Rule 10b5‑1 plans; such trades signal liquidity-taking rather than new negative information. SEC Form 4 (Andrew D. Dickinson)
- Neutral Sentiment: Gilead is expected to report quarterly results soon, which typically increases volatility as investors position around guidance and product trends. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
- Neutral Sentiment: Media and analyst coverage (valuation pieces and trending‑stock notes) are driving attention but not yet altering fundamentals. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
- Negative Sentiment: RBC reported that persistence for Gilead’s HIV drug nine months after launch is weaker than expected — a potential hit to longer‑term revenue/kicker assumptions for the new product. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
- Negative Sentiment: Zacks Research trimmed Q1–Q4 FY2026 EPS forecasts, lowering near‑term earnings expectations and increasing downside risk to consensus estimates. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
- Negative Sentiment: Broader health‑care stocks were softer late in the session, which amplified downward pressure on Gilead despite some stock‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon
Gilead Sciences Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
See Also
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
